4. Austrian consensus-statement for diagnosis and therapy of Hepatitis B 2009;4. Österreichischer Konsensusbericht zur Diagnose und Therapie der Hepatitis B 2009

Wiener Klinische Wochenschrift

Volumn 122, Issue 9-10, 2010, Pages 280-302

  Peck Radosavljevic, Markus ^a   Deutsch, Johann ^a   Ferenci, Peter ^a   Graziadei, Ivo ^a   Hofer, Harald ^a   Holzmann, Heidemarie ^a   Huber, Wolf Dietrich ^a   Laferl, Herman ^a   Maieron, Andreas ^a   Stauber, Rudolf ^a   Vogel, Wolfgang ^a  

^a Arbeitsgruppe Leber ^*  (Austria)

Author keywords

Entecavir; Hepatitis B; Interferon; Lamivudine; Liver transplantation; Nucleoside; Nucleotide; Telbivudine; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; DNA POLYMERASE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOTIDE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

AUSTRIA; CONFERENCE PAPER; GENOTYPE; HEPATITIS B; HEPATITIS DELTA VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER BIOPSY; LIVER TRANSPLANTATION; PASSIVE IMMUNIZATION; PATHOGENESIS; PRACTICE GUIDELINE; PROPHYLAXIS; RELAPSE; SCREENING TEST; ARTICLE; CLINICAL PRACTICE; STANDARD;

AUSTRIA; HEPATITIS B; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 77955685793     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-009-1298-0     Document Type: Conference Paper

References (144)

1. M Cornberg U Protzer MM Dollinger J Petersen H Wedemeyer T Berg W Jilg, et al. 2007 Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection Z Gastroenterol 45 1281 1328 1:CAS:528:DC%2BD1cXjt12ks7k%3D 18080231
2. World Health Organisation (2001) Hepatitis Delta. Electronic Citation In
3. D Lavanchy 2004 Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 97 107 1:STN:280:DC%2BD2c7gs1Whug%3D%3D 14996343
4. D Ganem AM Prince 2004 Hepatitis B virus infection-natural history and clinical consequences N Engl J Med 350 1118 1129 1:CAS:528:DC%2BD2cXitV2qurs%3D 15014185
5. B Rehermann M Nascimbeni 2005 Immunology of hepatitis B virus and hepatitis C virus infection Nat Rev Immunol 5 215 229 1:CAS:528: DC%2BD2MXhslSju7k%3D 15738952
6. JF Perz GL Armstrong LA Farrington YJ Hutin BP Bell 2006 The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 529 538 16879891
7. CJ Chen HI Yang J Su CL Jen SL You SN Lu GT Huang, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D 16391218
8. UH Iloeje HI Yang J Su CL Jen SL You CJ Chen 2006 Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 678 686 16530509
9. M Kohmoto M Enomoto A Tamori D Habu T Takeda N Kawada H Sakaguchi, et al. 2005 Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers J Med Virol 75 235 239 1:CAS:528:DC%2BD2MXntFyhtA%3D%3D 15602726
10. Robert-Koch-Institut 2006 Zur Situation wichtiger Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2005 Epidem Bull 46 399 410
11. G Chen W Lin F Shen UH Iloeje WT London AA Evans 2006 Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study Am J Gastroenterol 101 1797 1803 16817842
12. H Scheiblauer H Soboll S Nick 2006 Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection J Med Virol 78 Suppl 1 S66 S70 1:CAS:528:DC%2BD28Xnsl2lurw%3D 16622881
13. DR Palmer KR Perry PP Mortimer JV Parry 1996 Variation in the sensitivity of HBsAg screening kits Transfus Med 6 311 317 1:STN:280:DyaK2s7js1Wquw%3D%3D 8981725
14. B Weber 2005 Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact J Clin Virol 32 102 112 1:CAS:528: DC%2BD2MXkvFChuw%3D%3D 15653412
15. G Colloredo G Bellati G Leandro P Colombatto A Rho F Bissoli MR Brunetto, et al. 1996 Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values J Hepatol 25 644 648 1:STN:280: DyaK2s%2Fpt12kug%3D%3D 8938540
16. A Rodella C Galli L Terlenghi F Perandin C Bonfanti N Manca 2006 Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B J Clin Virol 37 206 212 1:CAS:528:DC%2BD28XhtVygt7fN 16893678
17. Mertens T, Haller OA, Klenk HD (2004) Diagnostik und Therapie von Viruskrankheiten: Leitlinien der Gesellschaft für Virologie. Urban und Fischer Verlag, München
18. P Grob W Jilg H Bornhak G Gerken W Gerlich S Gunther G Hess, et al. 2000 Serological pattern "anti-HBc alone": report on a workshop J Med Virol 62 450 455 1:STN:280:DC%2BD3M%2FovF2lug%3D%3D 11074473
19. A Knoll A Hartmann H Hamoshi K Weislmaier W Jilg 2006 Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance World J Gastroenterol 12 1255 1260 16534880
20. A Berger HW Doerr HF Rabenau B Weber 2000 High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen Intervirology 43 71 76 1:CAS:528:DC%2BD3cXntFGisr8%3D 10971123
21. W Jilg B Hottentrager K Weinberger K Schlottmann E Frick A Holstege J Scholmerich, et al. 2001 Prevalence of markers of hepatitis B in the adult German population J Med Virol 63 96 102 1:STN:280:DC%2BD3M3isVyltg%3D%3D 11170044
22. S Awerkiew M Daumer M Reiser UC Wend H Pfister R Kaiser WR Willems, et al. 2007 Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient J Clin Virol 38 83 86 17134939
23. TH Westhoff F Jochimsen A Schmittel M Stoffler-Meilicke JH Schafer W Zidek WH Gerlich, et al. 2003 Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy Blood 102 1930 1:CAS:528:DC%2BD3sXntFaqsL4%3D 12930732
24. P Schirmacher WE Fleig A Tannapfel C Langner V Dries L Terracciano H Denk, et al. 2004 Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference of the German Society of Pathology, of the German Society for Digestive and Metabolic Diseases and of Compensated Hepatitis (HepNet) Pathologe 25 337 348 1:STN:280:DC%2BD2cvjsVygtg%3D%3D 15278290
25. H Wedemeyer M Cornberg B Tegtmeyer H Frank HL Tillmann MP Manns 2004 Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication Clin Microbiol Infect 10 70 72 1:STN:280:DC%2BD2c%2FgvFGmsQ%3D%3D 14706089
26. Terminology, structure and laboratory diagnosis of hepatitis viruses. In: Gerlich WH, Thomssen R, Bircher J, Benhamou JP, McIntyre N, Rizetto M, Rhodes J (eds) Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1999; 828-869
27. M Rizzetto D Hepatitis 2000 Virology, clinical and epidemiological aspects Acta Gastroenterol Belg 63 221 224 1:STN:280:DC%2BD3cvnsFSrsQ%3D%3D 10925472
28. M Sherman KM Peltekian C Lee 1995 Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population Hepatology 22 432 438 1:STN:280:DyaK2Mzmt1WltA%3D%3D 7543434
29. B Yang B Zhang Y Xu W Wang Y Shen A Zhang Z Xu 1997 Prospective study of early detection for primary liver cancer J Cancer Res Clin Oncol 123 357 360 1:STN:280:DyaK2szmsFCktA%3D%3D 9222303
30. JL Dienstag 2002 The role of liver biopsy in chronic hepatitis C Hepatology 36 S152 S160 12407589
31. R del Canho PM Grosheide JA Mazel RA Heijtink WC Hop LJ Gerards GC de Gast, et al. 1997 Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity Vaccine 15 1624 1630 1:STN:280:DyaK1c%2FjtFaktA%3D%3D 9364693
32. AS Lok BJ McMahon 2007 Chronic hepatitis B Hepatology 45 507 539 1:CAS:528:DC%2BD2sXisVKns7o%3D 17256718
33. EB Keeffe DT Dieterich SH Han IM Jacobson P Martin ER Schiff H Tobias, et al. 2006 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update Clin Gastroenterol Hepatol 4 936 962 1:CAS:528:DC%2BD28XptFWmtrg%3D 16844425
34. DD Richman 2000 The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B Hepatology 32 866 867 1:STN:280: DC%2BD3cvpsFKlug%3D%3D 11003636
35. S Locarnini 2003 Hepatitis B viral resistance: mechanisms and diagnosis J Hepatol 39 Suppl 1 S124 S132 1:CAS:528:DC%2BD3sXnt1yjtbk%3D 14708690
36. JM Pawlotsky G Dusheiko A Hatzakis D Lau G Lau TJ Liang S Locarnini, et al. 2008 Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach Gastroenterology 134 405 415 18242209
37. MR Brunetto F Oliveri B Coco G Leandro P Colombatto JM Gorin F Bonino 2002 Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study J Hepatol 36 263 270 1:CAS:528:DC%2BD38Xit1eis7s%3D 11830339
38. WG Cooksley T Piratvisuth SD Lee V Mahachai YC Chao T Tanwandee A Chutaputti, et al. 2003 Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B J Viral Hepat 10 298 305 1:STN:280:DC%2BD3szksVOquw%3D%3D 12823597
39. A Craxi D Di Bona C Camma 2003 Interferon-alpha for HBeAg-positive chronic hepatitis B J Hepatol 39 Suppl 1 S99 S105 1:CAS:528:DC%2BD3sXnt1yjtb0%3D 14708686
40. G Fattovich L Brollo S Boscaro P Pontisso G Giustina D Criscuolo D Maladorno, et al. 1989 Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B J Hepatol 9 331 337 1:STN:280:DyaK3c7htV2gtw%3D%3D 2691568
41. HL Janssen M van Zonneveld H Senturk S Zeuzem US Akarca Y Cakaloglu C Simon, et al. 2005 Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 123 129 1:CAS:528:DC%2BD2MXhvF2gsQ%3D%3D 15639293
42. SM Lin ML Yu CM Lee RN Chien IS Sheen CM Chu YF Liaw 2007 Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma J Hepatol 46 45 52 1:CAS:528:DC%2BD28Xht1Krs7vK 17107734
43. P Marcellin GK Lau F Bonino P Farci S Hadziyannis R Jin ZM Lu, et al. 2004 Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 1206 1217 1:CAS:528:DC%2BD2cXns12rsr0%3D 15371578
44. RP Perrillo RG Gish M Peters EB Keeffe A Alberti M Buti WG Cooksley, et al. 2006 Chronic hepatitis B: a critical appraisal of current approaches to therapy Clin Gastroenterol Hepatol 4 233 248 16469685
45. P Lampertico M Vigano E Manenti M Iavarone G Lunghi M Colombo 2005 Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine Hepatology 42 1414 1419 1:CAS:528: DC%2BD2MXhtlGns7vP 16317671
46. S Locarnini A Hatzakis J Heathcote EB Keeffe TJ Liang D Mutimer JM Pawlotsky, et al. 2004 Management of antiviral resistance in patients with chronic hepatitis B Antivir Ther 9 679 693 1:CAS:528:DC%2BD2cXhtVKqsb%2FJ 15535405
47. JL Dienstag ER Schiff TL Wright RP Perrillo HW Hann Z Goodman L Crowther, et al. 1999 Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1256 1263 1:CAS:528:DyaK1MXnt1Cqs78%3D 10528035
48. YF Liaw JJ Sung WC Chow G Farrell CZ Lee H Yuen T Tanwandee, et al. 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 1521 1531 1:CAS:528:DC%2BD2cXot1Kls7w%3D 15470215
49. M van Zonneveld AB van Nunen HG Niesters RA de Man SW Schalm HL Janssen 2003 Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection J Viral Hepat 10 294 297 1:STN:280: DC%2BD3s3ps1yiuw%3D%3D 12823596
50. V Di Marco A Marzano P Lampertico P Andreone T Santantonio PL Almasio M Rizzetto, et al. 2004 Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine Hepatology 40 883 891 1:CAS:528:DC%2BD2cXptV2qt7Y%3D 15382125
51. HL Chan EJ Heathcote P Marcellin CL Lai M Cho YM Moon YC Chao, et al. 2007 Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial Ann Intern Med 147 745 754 17909201
52. CL Lai E Gane YF Liaw CW Hsu S Thongsawat Y Wang Y Chen, et al. 2007 Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 357 2576 2588 1:CAS:528:DC%2BD2sXhsVKht7nF 18094378
53. CL Lai N Leung EK Teo M Tong F Wong HW Hann S Han, et al. 2005 A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B Gastroenterology 129 528 536 1:CAS:528:DC%2BD2MXpvVWmsLs%3D 16083710 (Pubitemid 41096641)
54. TT Chang RG Gish R de Man A Gadano J Sollano YC Chao AS Lok, et al. 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 1001 1010 1:CAS:528:DC%2BD28XitFWms7Y%3D 16525137 (Pubitemid 43357804)
55. TT Chang RG Gish SJ Hadziyannis J Cianciara M Rizzetto ER Schiff G Pastore, et al. 2005 A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients Gastroenterology 129 1198 1209 1:CAS:528:DC%2BD2MXhtFyltb%2FJ 16230074
56. CL Lai M Rosmawati J Lao H Van Vlierberghe FH Anderson N Thomas D Dehertogh 2002 Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection Gastroenterology 123 1831 1838 1:CAS:528:DC%2BD38Xps1yktbw%3D 12454840
57. CL Lai D Shouval AS Lok TT Chang H Cheinquer Z Goodman D DeHertogh, et al. 2006 Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 1011 1020 1:CAS:528:DC%2BD28XitFWlsrY%3D 16525138 (Pubitemid 43357805)
58. DJ Tenney RE Rose CJ Baldick KA Pokornowski BJ Eggers J Fang MJ Wichroski, et al. 2009 Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 1503 1514 1:CAS:528:DC%2BD1MXlslKmurw%3D 19280622
59. R Colonno R Rose K Pokornowski C Baldick B Eggers D Yu 2007 Four year assessment of entecavir resistance in nucleoside naive and lamivudine refractory patients J Hepatol 46 S294 (Abstract)
60. SJ Hadziyannis NC Tassopoulos EJ Heathcote TT Chang G Kitis M Rizzetto P Marcellin, et al. 2003 Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med 348 800 807 1:CAS:528:DC%2BD3sXhsFKju7w%3D 12606734 (Pubitemid 36245756)
61. MG Peters H Hann Hw P Martin EJ Heathcote P Buggisch R Rubin M Bourliere, et al. 2004 Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 91 101 1:CAS:528:DC%2BD2cXhtFGntLo%3D 14699491
62. P Marcellin TT Chang SG Lim MJ Tong W Sievert ML Shiffman L Jeffers, et al. 2003 Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 808 816 1:CAS:528:DC%2BD3sXhsFKisrc%3D 12606735 (Pubitemid 36245757)
63. SJ Hadziyannis NC Tassopoulos EJ Heathcote TT Chang G Kitis M Rizzetto P Marcellin, et al. 2006 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years Gastroenterology 131 1743 1751 1:CAS:528:DC%2BD2sXhtFyltLs%3D 17087951 (Pubitemid 44958517)
64. P Marcellin EJ Heathcote M Buti E Gane RA de Man Z Krastev G Germanidis, et al. 2008 Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2442 2455 1:CAS:528:DC%2BD1cXhsVCrurjL 19052126
65. F van Bommel B Zollner C Sarrazin U Spengler D Huppe B Moller HH Feucht, et al. 2006 Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy Hepatology 44 318 325 16871563
66. JH Hoofnagle E Doo TJ Liang R Fleischer AS Lok 2007 Management of hepatitis B: summary of a clinical research workshop Hepatology 45 1056 1075 1:CAS:528:DC%2BD2sXltlWitb0%3D 17393513
67. F Gunsar US Akarca G Ersoz AC Kobak Z Karasu G Yuce T Ilter, et al. 2005 Two-year interferon therapy with or without ribavirin in chronic delta hepatitis Antivir Ther 10 721 726 1:CAS:528:DC%2BD2MXhtF2ntbbO 16218171
68. GA Niro A Ciancio GB Gaeta A Smedile A Marrone A Olivero M Stanzione, et al. 2006 Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta Hepatology 44 713 720 1:CAS:528: DC%2BD28XhtVeqt7bI 16941685
69. GA Niro A Ciancio HL Tillman M Lagget A Olivero F Perri R Fontana, et al. 2005 Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study Aliment Pharmacol Ther 22 227 232 1:CAS:528:DC%2BD2MXhtVags77P 16091060
70. BJ McMahon WL Alward DB Hall WL Heyward TR Bender DP Francis JE Maynard 1985 Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state J Infect Dis 151 599 603 1:STN:280:DyaL2M7jt12hsg%3D%3D 3973412
71. NC Tassopoulos GJ Papaevangelou MH Sjogren A Roumeliotou-Karayannis JL Gerin RH Purcell 1987 Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults Gastroenterology 92 1844 1850 1:STN:280:DyaL2s7ptFKmsQ%3D%3D 3569758
72. M Kumar S Satapathy R Monga K Das S Hissar C Pande BC Sharma, et al. 2007 A randomized controlled trial of lamivudine to treat acute hepatitis B Hepatology 45 97 101 1:CAS:528:DC%2BD2sXht1arsbg%3D 17187417
73. LA Lettau JG McCarthy MH Smith SC Hadler LJ Morse T Ukena R Bessette, et al. 1987 Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts N Engl J Med 317 1256 1262 1:STN:280:DyaL1c%2FjvFSjug%3D%3D 3670348
74. HL Tillmann H Wedemeyer MP Manns 2003 Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation J Hepatol 39 Suppl 1 S206 S211 1:CAS:528:DC%2BD3sXnt1yju74%3D 14708705
75. SK Acharya S Dasarathy TL Kumer S Sushma KS Prasanna A Tandon V Sreenivas, et al. 1996 Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome Hepatology 23 1448 1455 1:STN:280:DyaK283ktlWltw%3D%3D 8675163
76. J Bernuau A Goudeau T Poynard F Dubois G Lesage B Yvonnet C Degott, et al. 1986 Multivariate analysis of prognostic factors in fulminant hepatitis B Hepatology 6 648 651 1:STN:280:DyaL283ns1ekug%3D%3D 3732998
77. JG O'Grady AE Gimson CJ O'Brien A Pucknell RD Hughes R Williams 1988 Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure Gastroenterology 94 1186 1192 3280388
78. LA Kondili H Osman D Mutimer 2004 The use of lamivudine for patients with acute hepatitis B (a series of cases) J Viral Hepat 11 427 431 1:STN:280:DC%2BD2cvltVOgtw%3D%3D 15357647
79. H Schmilovitz-Weiss Z Ben-Ari E Sikuler E Zuckerman W Sbeit Z Ackerman R Safadi, et al. 2004 Lamivudine treatment for acute severe hepatitis B: a pilot study Liver Int 24 547 551 1:CAS:528:DC%2BD2MXmtVaitQ%3D%3D 15566503
80. HL Tillmann J Hadem L Leifeld K Zachou A Canbay C Eisenbach I Graziadei, et al. 2006 Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience J Viral Hepat 13 256 263 1:STN:280:DC%2BD283gsFOqsQ%3D%3D 16611192
81. N Torii K Hasegawa M Ogawa E Hashimo N Hayashi 2002 Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B Hepatol Res 24 34 1:CAS:528:DC%2BD38XntVajsbY%3D 12243790
82. M Cornberg U Protzer MM Dollinger J Petersen H Wedemeyer T Berg W Jilg, et al. 2007 Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-) Infection: upgrade of the guideline, AWMF-Register 021/011 Z Gastroenterol 45 525 574 1:STN:280:DC%2BD2svovVKmtA%3D%3D 17554641
83. MA McMahon BL Jilek TP Brennan L Shen Y Zhou M Wind-Rotolo S Xing, et al. 2007 The HBV drug entecavir - effects on HIV-1 replication and resistance N Engl J Med 356 2614 2621 1:CAS:528:DC%2BD2sXmslKjs7o%3D 17582071
84. G Lalazar D Rund D Shouval 2007 Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies Br J Haematol 136 699 712 1:CAS:528:DC%2BD2sXjvFWmtb0%3D 17338776
85. GK Lau T Piratvisuth KX Luo P Marcellin S Thongsawat G Cooksley E Gane, et al. 2005 Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2682 2695 1:CAS:528:DC%2BD2MXls1SktL8%3D 15987917
86. ER Schiff CL Lai S Hadziyannis P Neuhaus N Terrault M Colombo HL Tillmann, et al. 2003 Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients Hepatology 38 1419 1427 1:CAS:528:DC%2BD2cXpsVGk 14647053
87. E Schiff CL Lai S Hadziyannis P Neuhaus N Terrault M Colombo H Tillmann, et al. 2007 Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results Liver Transpl 13 349 360 17326221
88. YF Liaw 2005 Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma Semin Liver Dis 25 Suppl 1 40 47 16103980
89. CM Chu YF Liaw 2006 Hepatitis B virus-related cirrhosis: natural history and treatment Semin Liver Dis 26 142 152 1:CAS:528:DC%2BD28Xltlegsr8%3D 16673292
90. RJ Fontana 2003 Management of patients with decompensated HBV cirrhosis Semin Liver Dis 23 89 100 1:CAS:528:DC%2BD3sXisFamtrY%3D 12616454
91. RJ Fontana EB Keeffe W Carey M Fried R Reddy KV Kowdley C Soldevila-Pico, et al. 2002 Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B Liver Transpl 8 433 439 12004342
92. D Kapoor RC Guptan SM Wakil SN Kazim R Kaul SR Agarwal S Raisuddin, et al. 2000 Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis J Hepatol 33 308 312 1:CAS:528:DC%2BD3cXlvVylu7Y%3D 10952249
93. JY Lau VG Bain SE Davies JG O'Grady A Alberti GJ Alexander R Williams 1992 High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis Gastroenterology 102 956 962 1:STN:280: DyaK387msFShug%3D%3D 1537531
94. JG O'Grady HM Smith SE Davies HM Daniels PT Donaldson KC Tan B Portmann, et al. 1992 Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications J Hepatol 14 104 111 1737910
95. D Samuel R Muller G Alexander L Fassati B Ducot JP Benhamou H Bismuth 1993 Liver transplantation in European patients with the hepatitis B surface antigen [see comments] N Engl J Med 329 1842 1847 1:STN:280: DyaK2c%2Fmslaisw%3D%3D 8247035
96. JS Markowitz P Martin AJ Conrad JF Markmann P Seu H Yersiz JA Goss, et al. 1998 Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin Hepatology 28 585 589 1:STN:280:DyaK1czlvFWquw%3D%3D 9696028
97. T Steinmuller D Seehofer N Rayes AR Muller U Settmacher S Jonas R Neuhaus, et al. 2002 Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease Hepatology 35 1528 1535 12029640 (Pubitemid 34966909)
98. N Terrault B Roche D Samuel 2005 Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective Liver Transpl 11 716 732 15973718
99. RW McGory MB Ishitani WM Oliveira WC Stevenson CS McCullough RC Dickson SH Caldwell, et al. 1996 Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization Transplantation 61 1358 1364 1:STN:280:DyaK283hsFOgtA%3D%3D 8629297
100. RD Anderson S Chinnakotla L Guo RP Perrillo GB Klintmalm GL Davis 2007 Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens Clin Transplant 21 510 517 17645711
101. EJ Gane PW Angus S Strasser DH Crawford J Ring GP Jeffrey GW McCaughan 2007 Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation Gastroenterology 132 931 937 1:CAS:528:DC%2BD2sXkslCjurY%3D 17383422
102. J Rosenau N Hooman K Rifai T Solga HL Tillmann E Grzegowski B Nashan, et al. 2006 Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response Transpl Int 19 828 833 1:CAS:528:DC%2BD28XhtFGru7vI 16961775
103. A Sanchez-Fueyo A Rimola L Grande J Costa A Mas M Navasa I Cirera, et al. 2000 Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation Hepatology 31 496 501 1:STN:280: DC%2BD3c7it1emsQ%3D%3D 10655276
104. P Starkel M Stoffel J Lerut Y Horsmans 2005 Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients Liver Transpl 11 1228 1234 16184571
105. U Bienzle M Gunther R Neuhaus P Vandepapeliere J Vollmar A Lun P Neuhaus 2003 Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease Hepatology 38 811 819 1:CAS:528:DC%2BD3sXovFGhtLY%3D 14512868
106. F Fabrizi P Martin V Dixit F Kanwal G Dulai 2005 HB-sAg seropositive status and survival after renal transplantation: meta-analysis of observational studies Am J Transplant 5 2913 2921 1:CAS:528:DC%2BD2MXhtlGns7zE 16303005 (Pubitemid 43923952)
107. S Fornairon S Pol C Legendre F Carnot MF Mamzer-Bruneel C Brechot H Kreis 1996 The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection Transplantation 62 297 299 1:STN:280:DyaK28zkslKitg%3D%3D 8755832
108. P Mathurin C Mouquet T Poynard C Sylla H Benalia C Fretz V Thibault, et al. 1999 Impact of hepatitis B and C virus on kidney transplantation outcome Hepatology 29 257 263 1:STN:280:DyaK1M%2FotFOjtw%3D%3D 9862875
109. E Prakoso SI Strasser DJ Koorey D Verran GW McCaughan 2006 Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors Clin Transplant 20 369 373 16824156
110. AM Roque-Afonso C Feray D Samuel D Simoneau B Roche JF Emile M Gigou, et al. 2002 Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors Gut 50 95 99 1:CAS:528:DC%2BD38XltVOqtg%3D%3D 11772974
111. TM De Feo F Poli F Mozzi MP Moretti M Scalamogna 2005 Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study Transplant Proc 37 1238 1239 1:STN:280: DC%2BD2M3hsFShsQ%3D%3D 15848681
112. F Fabrizio S Bunnapradist P Martin 2002 Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage J Nephrol 15 605 613 12495272
113. P Fytili S Ciesek MP Manns H Wedemeyer M Neipp F Helfritz J Klempnauer, et al. 2006 Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients Transplantation 81 808 809 16534488
114. H Lackner A Moser M Benesch J Deutsch HH Kessler R Kerbl W Schwinger, et al. 2002 Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy J Clin Virol 25 Suppl 3 S73 S79 1:CAS:528:DC%2BD38XptFeqsbs%3D 12467780
115. M Sacher G Eder K Baumgarten H Thaler 1983 [Vertical transmission of hepatitis B. Results of a prospective study 1978 to 1981] Wien Klin Wochenschr 95 447 451 1:STN:280:DyaL2c%2FkslWisw%3D%3D 6636775
116. JC Chen ML Chang JN Lin HS Lai CC Chen WJ Chen WT Hung 2005 Comparison of childhood hepatic malignancies in a hepatitis B hyper-endemic area World J Gastroenterol 11 5289 5294 16149134
117. S Ranger-Rogez F Denis 2004 Hepatitis B mother - to - child transmission Expert Rev Anti Infect Ther 2 133 145 1:CAS:528:DC%2BD2cXisFCqtrg%3D 15482178
118. F Bortolotti M Guido S Bartolacci P Cadrobbi C Crivellaro F Noventa G Morsica, et al. 2006 Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study Hepatology 43 556 562 16496323
119. D Kelly 2004 Viral hepatitis in children Adv Exp Med Biol 549 83 90 15250519
120. J Deutsch H Rosegger G Lanzer GF Füger G Slawitsch H Nöres 1993 Wirksamkeit der simultanen passiv-aktiven Hepatitis B - Impfung von Neugeborenen Päd Pädol 28 109
121. P Wintermeyer P Gerner S Gehring A Karimi S Wirth 2006 Prevalence of hepatitis B virus precore stop codon mutations in chronically infected children World J Gastroenterol 12 2235 2238 1:CAS:528:DC%2BD28XltFamt7w%3D 16610027
122. B Laubscher M Gehri M Roulet S Wirth P Gerner 2005 Survival of infantile fulminant hepatitis B and treatment with Lamivudine J Pediatr Gastroenterol Nutr 40 518 520 1:STN:280:DC%2BD2M7mtlamsg%3D%3D 15795605
123. F Bortolotti P Jara C Barbera GV Gregorio A Vegnente L Zancan L Hierro, et al. 2000 Long term effect of alpha interferon in children with chronic hepatitis B Gut 46 715 718 1:CAS:528:DC%2BD3cXjsVSgsrs%3D 10764718
124. AR Gigliotti F Fioredda R Giacchino 2003 Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation J Pediatr Hematol Oncol 25 184 192 12621235
125. X Hom NR Little SD Gardner MM Jonas 2004 Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection Pediatr Infect Dis J 23 441 445 15131468
126. MM Jonas J Mizerski IB Badia JA Areias KB Schwarz NR Little MJ Greensmith, et al. 2002 Clinical trial of lamivudine in children with chronic hepatitis B N Engl J Med 346 1706 1713 1:CAS:528:DC%2BD38XktVansLc%3D 12037150
127. H Vo Thi Diem A Bourgois P Bontems P Goyens JP Buts F Nackers R Tonglet, et al. 2005 Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls J Pediatr Gastroenterol Nutr 40 141 145 15699686
128. F Bortolotti 2003 Treatment of chronic hepatitis B in children J Hepatol 39 Suppl 1 S200 S205 1:CAS:528:DC%2BD3sXnt1yjurc%3D 14708704
129. B Dikici F Ozgenc AG Kalayci S Targan T Ozkan A Selimoglu T Doganci, et al. 2004 Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study J Gastroenterol Hepatol 19 127 133 14731120
130. H Gregorek K Dzierzanowska-Fangrat M Woynarowski P Jozwiak E Witkowska-Vogtt J Socha M Syczewska, et al. 2005 Persistence of HBV-DNA in children with chronic hepatitis B who seroconverted to anti-HBs antibodies after interferon-alpha therapy: correlation with specific IgG subclass responses to HBsAg J Hepatol 42 486 490 1:CAS:528:DC%2BD2MXitFyrurc%3D 15763334
131. C Hartman D Berkowitz O Eshach-Adiv B Hino N Rimon I Satinger T Kra-Oz, et al. 2006 Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon J Pediatr Gastroenterol Nutr 43 494 498 1:CAS:528:DC%2BD28XhtVKjtLvJ 17033525
132. YH Ni FC Huang TC Wu MS Kong YM Jeng PJ Chen DJ Tsuei, et al. 2005 Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients Pediatr Int 47 372 377 1:CAS:528:DC%2BD28XhsFGrurs%3D 16091071
133. F Ozgenc C Arikan RY Sertoz D Nart S Aydogdu RV Yagci 2004 Effect of long-term lamivudine in chronic hepatitis B virus-infected children Antivir Ther 9 729 732 1:CAS:528:DC%2BD2cXhtVKqsb%2FL 15535410
134. EM Sokal DA Kelly J Mizerski IB Badia JA Areias KB Schwarz A Vegnente, et al. 2006 Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B Hepatology 43 225 232 1:CAS:528:DC%2BD28XhvVSgu7Y%3D 16440364
135. GV Zuccotti C Cucchi V Gracchi E D'Auria E Riva A Tagger 2002 A 1-year trial of lamivudine for chronic hepatitis B in children J Int Med Res 30 200 202 1:CAS:528:DC%2BD38Xkt1Sgur8%3D 12025529
136. SA Akman SC Okcu O Halicioglu S Sutcuoglu M Anil A Kizilgunesler AR
137. L D'Antiga M Aw M Atkins A Moorat D Vergani G Mieli-Vergani 2006 Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study J Pediatr 148 228 233 16492434
138. B Dikici M Bosnak V Bosnak A Dagli A Ece RV Yagci K Haspolat 2002 Combination therapy for children with chronic hepatitis B virus infection J Gastroenterol Hepatol 17 1087 1091 1:CAS:528:DC%2BD38Xos1Cjtb8%3D 12201869
139. B Dikici M Bosnak IH Kara O Dogru A Dagli F Gurkan K Haspolat 2001 Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection Pediatr Infect Dis J 20 988 992 1:STN:280:DC%2BD3Mrmt1OitA%3D%3D 11642634
140. A Kansu T Doganci SA Akman R Artan N Kuyucu AG Kalayci B Dikici, et al. 2006 Comparison of two different regimens of combined interferon-alpha2a and lamivudine therapy in children with chronic hepatitis B infection Antivir Ther 11 255 261 1:CAS:528:DC%2BD28Xkt1Knur8%3D 16640106
141. IN Saltik-Temizel N Kocak H Demir 2005 Lamivudine and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection J Clin Gastroenterol 39 68 70 15599215
142. IN Saltik-Temizel N Kocak H Demir 2004 Interferon-alpha and lamivudine combination therapy of children with chronic hepatitis b infection who were interferon-alpha nonresponders Pediatr Infect Dis J 23 466 468 15131475
143. Sanitätsrates Ido. Impfplan 2008. In: Familie BfGu (ed) Wien: Österreischische Ärztezeitung; 2008. pp 22-54
144. JB Hill JS Sheffield MJ Kim JM Alexander B Sercely GD Wendel 2002 Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers Obstet Gynecol 99 1049 1052 12052598